In the 'auditory intersensory' conditions, participants reported whether the auditory target was shorter or longer than all other auditory stimuli in the trial; conversely, in the 'visual intersensory' conditions, participants judged whether the visual target was shorter or longer than all other visual stimuli in the trial.
Indeed, we show that multiple trials in a context of reduced Ca2+ are treated by the nervous system as a single trial; conversely, a single trial in a context of increased Ca2+ mimics the effect of multiple trials.
A second point to consider is the absence of a symptomatic effect of ASU-E in this trial conversely to previous shorter symptom modification randomised controlled trials of ASU-E.
The SSD started at 200 ms and varied from one stop trial to the next according to a staircase procedure: if the subject succeeded in withholding the response, the SSD increased by 64 ms, making it more difficult to succeed again in the next stop trial; conversely, if a subject failed, SSD decreased by 64 ms, making it easier for the next stop trial.
None of the reviews could identify any strategies that were clearly found to increase recruitment to trials, but conversely none of the strategies identified could be unequivocally said to be ineffective at increasing recruitment due to small numbers of studies testing each strategy and methodological weaknesses.
It may also be that patients who require eight months of treatment for alcohol may require more than the six sessions of cognitive therapy for social phobia provided in this trial and, conversely, that those who have less chronic or severe alcohol problems may derive greater benefits from dual treatment than did patients in the above study.
Conversely, trials with dual antiplatelet therapy for six months or more showed no increase in risk from using sirolimus eluting stents compared with bare metal stents.
Conversely, clinical trials have shown that drug-eluting stents have significantly reduced ISR.
Conversely, negative trials included more recent trials with lower mortality rates in the control arm 17-399%) [2, 3, 6].
Conversely, on trials with no reward it should be negative (see Figure 1c).
